Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model

医学 系统回顾 梅德林 科克伦图书馆 英夫利昔单抗 心理干预 阿达木单抗 Golimumab公司 经济评价 家庭医学 随机对照试验 外科 疾病 护理部 内科学 法学 病理 政治学
作者
Rachel Archer,Paul Tappenden,Shijie Ren,Marrissa Martyn‐St James,Rebecca Harvey,Hasan Basarir,John Stevens,Christopher Carroll,Anna Cantrell,Alan Lobo,Sami Hoque
出处
期刊:Health Technology Assessment [NIHR Journals Library]
卷期号:20 (39): 1-326 被引量:63
标识
DOI:10.3310/hta20390
摘要

Background Ulcerative colitis (UC) is the most common form of inflammatory bowel disease in the UK. UC can have a considerable impact on patients’ quality of life. The burden for the NHS is substantial. Objectives To evaluate the clinical effectiveness and safety of interventions, to evaluate the incremental cost-effectiveness of all interventions and comparators (including medical and surgical options), to estimate the expected net budget impact of each intervention, and to identify key research priorities. Data sources Peer-reviewed publications, European Public Assessment Reports and manufacturers’ submissions. The following databases were searched from inception to December 2013 for clinical effectiveness searches and from inception to January 2014 for cost-effectiveness searches for published and unpublished research evidence: MEDLINE, EMBASE, Cumulative Index to Nursing and Allied Health Literature, The Cochrane Library including the Cochrane Systematic Reviews Database, Cochrane Controlled Trials Register, Database of Abstracts of Reviews of Effects, the Health Technology Assessment database and NHS Economic Evaluation Database; ISI Web of Science, including Science Citation Index, and the Conference Proceedings Citation Index-Science and Bioscience Information Service Previews. The US Food and Drug Administration website and the European Medicines Agency website were also searched, as were research registers, conference proceedings and key journals. Review methods A systematic review [including network meta-analysis (NMA)] was conducted to evaluate the clinical effectiveness and safety of named interventions. The health economic analysis included a review of published economic evaluations and the development of a de novo model. Results Ten randomised controlled trials were included in the systematic review. The trials suggest that adult patients receiving infliximab (IFX) [Remicade ® , Merck Sharp & Dohme Ltd (MSD)], adalimumab (ADA) (Humira ® , AbbVie) or golimumab (GOL) (Simponi ® , MSD) were more likely to achieve clinical response and remission than those receiving placebo (PBO). Hospitalisation data were limited, but suggested more favourable outcomes for ADA- and IFX-treated patients. Data on the use of surgical intervention were sparse, with a potential benefit for intervention-treated patients. Data were available from one trial to support the use of IFX in paediatric patients. Safety issues identified included serious infections, malignancies and administration site reactions. Based on the NMA, in the induction phase, all biological treatments were associated with statistically significant beneficial effects relative to PBO, with the greatest effect associated with IFX. For patients in response following induction, all treatments except ADA and GOL 100 mg at 32–52 weeks were associated with beneficial effects when compared with PBO, although these were not significant. The greatest effects at 8–32 and 32–52 weeks were associated with 100 mg of GOL and 5 mg/kg of IFX, respectively. For patients in remission following induction, all treatments except ADA at 8–32 weeks and GOL 50 mg at 32–52 weeks were associated with beneficial effects when compared with PBO, although only the effect of ADA at 32–52 weeks was significant. The greatest effects were associated with GOL (at 8–32 weeks) and ADA (at 32–52 weeks). The economic analysis suggests that colectomy is expected to dominate drug therapies, but for some patients, colectomy may not be considered acceptable. In circumstances in which only drug options are considered, IFX and GOL are expected to be ruled out because of dominance, while the incremental cost-effectiveness ratio for ADA versus conventional treatment is approximately £50,300 per QALY gained. Limitations The health economic model is subject to several limitations: uncertainty associated with extrapolating trial data over a lifetime horizon, the model does not consider explicit sequential pathways of non-biological treatments, and evidence relating to complications of colectomy was identified through consideration of approaches used within previous models rather than a full systematic review. Conclusions Adult patients receiving IFX, ADA or GOL were more likely to achieve clinical response and remission than those receiving PBO. Further data are required to conclusively demonstrate the effect of interventions on hospitalisation and surgical outcomes. The economic analysis indicates that colectomy is expected to dominate medical treatments for moderate to severe UC. Study registration This study is registered as PROSPERO CRD42013006883. Funding The National Institute for Health Research Health Technology Assessment programme.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
lhw发布了新的文献求助10
1秒前
wxr完成签到,获得积分10
1秒前
1秒前
MHM发布了新的文献求助10
1秒前
2024发布了新的文献求助10
1秒前
1秒前
Sledge发布了新的文献求助10
1秒前
2秒前
jinxia发布了新的文献求助10
3秒前
4秒前
4秒前
尹忆梅完成签到,获得积分10
4秒前
欢子发布了新的文献求助20
5秒前
好久不见发布了新的文献求助10
5秒前
等什么雨完成签到,获得积分10
5秒前
神秘人X发布了新的文献求助10
6秒前
zyx完成签到,获得积分10
6秒前
6秒前
Owen的应助被暴躁的惜筠采纳,获得10
6秒前
摆哥发布了新的文献求助10
6秒前
秋风的应助被罗杰采纳,获得10
6秒前
haifeng发布了新的文献求助10
6秒前
大个的应助被寒冷犀牛采纳,获得10
7秒前
7秒前
7秒前
慕青的应助被wanci采纳,获得20
7秒前
7秒前
8秒前
脑洞疼的应助被跳跃的寄瑶采纳,获得10
8秒前
OKOK发布了新的文献求助10
8秒前
茶博士完成签到,获得积分10
8秒前
舒心雅柔发布了新的文献求助10
8秒前
斯文败类的应助被泡泡茶壶采纳,获得10
9秒前
9秒前
10秒前
风眠故人发布了新的文献求助10
10秒前
Dong完成签到 ,获得积分10
11秒前
詹慧子发布了新的文献求助30
11秒前
目移完成签到,获得积分10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
Monte Cassino in the Middle Ages Volume I 310
JUSTIFICATION OF SMALL-SCALE MODELS: AN INDUSTRY PERSPECTIVE 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8157304
求助须知:如何正确求助?哪些是违规求助? 9553290
关于积分的说明 21713683
捐赠科研通 7746409
什么是DOI,文献DOI怎么找? 3426733
关于科研通互助平台的介绍 2551498
邀请新用户注册赠送积分活动 2470679